Pablo Villoslada-rekin lankidetzan egindako argitalpenak (11)

2014

  1. Differential neuroprotective effects of 5′-deoxy-5′- methylthioadenosine

    PLoS ONE, Vol. 9, Núm. 3

2013

  1. A trifluoromethyl analogue of celecoxib exerts beneficial effects in neuroinflammation

    PLoS ONE, Vol. 8, Núm. 12

  2. Oxidative Stress and Proinflammatory Cytokines Contribute to Demyelination and Axonal Damage in a Cerebellar Culture Model of Neuroinflammation

    PLoS ONE, Vol. 8, Núm. 2

2011

  1. Gain-of-function of P2X7 receptor gene variants in multiple sclerosis

    Cell Calcium, Vol. 50, Núm. 5, pp. 468-472

  2. Increased expression of cystine/glutamate antiporter in multiple sclerosis

    Journal of Neuroinflammation, Vol. 8

2009

  1. United Europeans for development of pharmacogenomics in multiple sclerosis network

    Pharmacogenomics, Vol. 10, Núm. 5, pp. 885-894

2008

  1. Association of an EAAT2 polymorphism with higher glutamate concentration in relapsing multiple sclerosis

    Journal of Neuroimmunology, Vol. 195, Núm. 1-2, pp. 194-198

  2. Refining genetic associations in multiple sclerosis

    The Lancet Neurology

2007

  1. Corrigendum to "Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans" [J. Neuroimmunol. 179 (2006) 108-116] (DOI:10.1016/j.jneuroim.2006.06.003)

    Journal of Neuroimmunology

  2. Pharmacogenomics of Type I interferon therapy: A survey of response-modifying genes

    Cytokine and Growth Factor Reviews

2006

  1. Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans

    Journal of Neuroimmunology, Vol. 179, Núm. 1-2, pp. 108-116